
    
      Children ages 8-17 years weighing between 70 -149 kilograms will be enrolled and treated with
      losartan (100 mg orally once per day) or matching placebo for 24 weeks. The hypothesis is
      that losartan will improve serum alanine aminotransferase (ALT) in children with pediatric
      NAFLD.
    
  